Biovail’s Ralivia receives approvable letter

Share this article:
An item appearing in the December issue of Medical Marketing and Media (Pipeline, page 10) incorrectly stated that Biovail's Ralivia ER (tramadol hydrochloride) had received FDA approval.
Biovail has received an approvable letter from the FDA for the drug, but it has yet to be approved.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions